Steroid hormone receptor expression in male breast cancer

C E Murphy; P J Carder; M R J Lansdown; V Speirs

doi:10.1016/j.ejso.2005.09.013

Steroid hormone receptor expression in male breast cancer

C E Murphy
, P J Carder
, M R J Lansdown
, V Speirs

University of Leeds

Research output: Contribution to journal › Article › peer-review

48 Citations (Scopus)

Abstract

AIMS: To investigate expression of the steroid hormone receptors estrogen receptor (ER)-alpha and -beta, progesterone receptor (PR) and androgen receptor (AR) in male breast cancer.

METHODS: Specimens from 16 male breast cancers were immunostained for ERalpha, ERbeta, PR and AR.

FINDINGS: Eighty-seven percent of tumours expressed ERalpha, 93% PR, 87% ERbeta and 87% AR. Staining for ERalpha and PR was confined exclusively to the nuclei of epithelial cells with some heterogeneity. Nuclear immunoreactivity was also observed with AR. Again this was restricted to epithelial cells but tended to be more uniform. ERbeta was seen in the nuclei of epithelial cells and also in stromal fibroblasts and lymphocytes. Analysis of serial sections revealed a similar pattern of staining with ERbeta and AR in epithelial cells.

CONCLUSIONS: In addition to expression of the better known steroid receptors, ERalpha, PR and AR, we have demonstrated a high rate of expression of ERbeta in male breast cancer. This is in keeping with the generally high steroid receptor expression seen in males. However, the abundance of ERbeta expressed in this small series of male breast cancer is in contrast to female breast cancer where ERbeta expression is often reduced.

Original language	English
Pages (from-to)	44-7
Number of pages	4
Journal	European Journal of Surgical Oncology
Volume	32
Issue number	1
DOIs	https://doi.org/10.1016/j.ejso.2005.09.013
Publication status	Published - Feb 2006
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biomarkers, Tumor
Breast Neoplasms, Male
Estrogen Receptor alpha
Estrogen Receptor beta
Humans
Immunohistochemistry
In Vitro Techniques
Male
Neoplasm Staging
Receptors, Androgen
Receptors, Progesterone
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Access to Document

10.1016/j.ejso.2005.09.013

Cite this

@article{66a4e1e70dd448ab8754a0c14c8cf43f,

title = "Steroid hormone receptor expression in male breast cancer",

abstract = "AIMS: To investigate expression of the steroid hormone receptors estrogen receptor (ER)-alpha and -beta, progesterone receptor (PR) and androgen receptor (AR) in male breast cancer.METHODS: Specimens from 16 male breast cancers were immunostained for ERalpha, ERbeta, PR and AR.FINDINGS: Eighty-seven percent of tumours expressed ERalpha, 93\% PR, 87\% ERbeta and 87\% AR. Staining for ERalpha and PR was confined exclusively to the nuclei of epithelial cells with some heterogeneity. Nuclear immunoreactivity was also observed with AR. Again this was restricted to epithelial cells but tended to be more uniform. ERbeta was seen in the nuclei of epithelial cells and also in stromal fibroblasts and lymphocytes. Analysis of serial sections revealed a similar pattern of staining with ERbeta and AR in epithelial cells.CONCLUSIONS: In addition to expression of the better known steroid receptors, ERalpha, PR and AR, we have demonstrated a high rate of expression of ERbeta in male breast cancer. This is in keeping with the generally high steroid receptor expression seen in males. However, the abundance of ERbeta expressed in this small series of male breast cancer is in contrast to female breast cancer where ERbeta expression is often reduced.",

keywords = "Biomarkers, Tumor, Breast Neoplasms, Male, Estrogen Receptor alpha, Estrogen Receptor beta, Humans, Immunohistochemistry, In Vitro Techniques, Male, Neoplasm Staging, Receptors, Androgen, Receptors, Progesterone, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't",

author = "Murphy, \{C E\} and Carder, \{P J\} and Lansdown, \{M R J\} and V Speirs",

year = "2006",

month = feb,

doi = "10.1016/j.ejso.2005.09.013",

language = "English",

volume = "32",

pages = "44--7",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Steroid hormone receptor expression in male breast cancer

AU - Murphy, C E

AU - Carder, P J

AU - Lansdown, M R J

AU - Speirs, V

PY - 2006/2

Y1 - 2006/2

N2 - AIMS: To investigate expression of the steroid hormone receptors estrogen receptor (ER)-alpha and -beta, progesterone receptor (PR) and androgen receptor (AR) in male breast cancer.METHODS: Specimens from 16 male breast cancers were immunostained for ERalpha, ERbeta, PR and AR.FINDINGS: Eighty-seven percent of tumours expressed ERalpha, 93% PR, 87% ERbeta and 87% AR. Staining for ERalpha and PR was confined exclusively to the nuclei of epithelial cells with some heterogeneity. Nuclear immunoreactivity was also observed with AR. Again this was restricted to epithelial cells but tended to be more uniform. ERbeta was seen in the nuclei of epithelial cells and also in stromal fibroblasts and lymphocytes. Analysis of serial sections revealed a similar pattern of staining with ERbeta and AR in epithelial cells.CONCLUSIONS: In addition to expression of the better known steroid receptors, ERalpha, PR and AR, we have demonstrated a high rate of expression of ERbeta in male breast cancer. This is in keeping with the generally high steroid receptor expression seen in males. However, the abundance of ERbeta expressed in this small series of male breast cancer is in contrast to female breast cancer where ERbeta expression is often reduced.

AB - AIMS: To investigate expression of the steroid hormone receptors estrogen receptor (ER)-alpha and -beta, progesterone receptor (PR) and androgen receptor (AR) in male breast cancer.METHODS: Specimens from 16 male breast cancers were immunostained for ERalpha, ERbeta, PR and AR.FINDINGS: Eighty-seven percent of tumours expressed ERalpha, 93% PR, 87% ERbeta and 87% AR. Staining for ERalpha and PR was confined exclusively to the nuclei of epithelial cells with some heterogeneity. Nuclear immunoreactivity was also observed with AR. Again this was restricted to epithelial cells but tended to be more uniform. ERbeta was seen in the nuclei of epithelial cells and also in stromal fibroblasts and lymphocytes. Analysis of serial sections revealed a similar pattern of staining with ERbeta and AR in epithelial cells.CONCLUSIONS: In addition to expression of the better known steroid receptors, ERalpha, PR and AR, we have demonstrated a high rate of expression of ERbeta in male breast cancer. This is in keeping with the generally high steroid receptor expression seen in males. However, the abundance of ERbeta expressed in this small series of male breast cancer is in contrast to female breast cancer where ERbeta expression is often reduced.

KW - Biomarkers, Tumor

KW - Breast Neoplasms, Male

KW - Estrogen Receptor alpha

KW - Estrogen Receptor beta

KW - Humans

KW - Immunohistochemistry

KW - In Vitro Techniques

KW - Male

KW - Neoplasm Staging

KW - Receptors, Androgen

KW - Receptors, Progesterone

KW - Comparative Study

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.ejso.2005.09.013

DO - 10.1016/j.ejso.2005.09.013

M3 - Article

C2 - 16260112

SN - 0748-7983

VL - 32

SP - 44

EP - 47

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 1

ER -

Steroid hormone receptor expression in male breast cancer

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this